Journal of Crohn's & colitis
-
Multicenter Study Comparative Study
Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
Both adalimumab [ADA] and infliximab [IFX] seem to be effective in the prevention of early postoperative endoscopic recurrence [EPER] after ileocaecal resection in Crohn's disease [CD] patients. There is lack of data with direct comparison between the two agents in the postoperative scenario. The aim of this study was to compare the rates of EPER in patients treated with ADA and IFX after ileocaecal resection for CD. ⋯ In this retrospective direct comparison between ADA and IFX therapy after ileocaecal resection, there was no significant difference between the two anti-TNF agents in terms of EPER rates. However, prospective randomised studies are needed to confirm these data and better define the role of each agent in the prevention of EPER.
-
Whether Crohn's disease [CD] is correlated with brain structural changes is unclear. This study examined changes in grey matter [GM] structures in CD patients and their correlation with psychological distress. ⋯ We suggest that the significant changes in GM structures in multiple brain regions of CD patients can be partially explained by the higher levels of anxiety and depression in these patients. Specific profiles of altered GM structures in CD patients were correlated with disease duration.